Abstract Library

#4338 Spot urine 5-HIAA creatinine ratio is comparable to 24hr urine collection for diagnosis of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) constitutes up to 20% of functional neuroendocrine neoplasms and can lead to carcinoid crisis (CC), a potentially fatal complication during invasive procedures. Urine 5-hydroxyindoleacetic acid (5HIAA) is the preferred diagnostic biomarker for CS and prognostic marker for CC. 5HIAA is collected over 24-hours with strict dietary restriction for the 2 days prior as well as the day of the collection. False positive and negative results can occur due to under and over-collection. Patient inconvenience also contributes to the low request rate of this test.

Conference:

Presenting Author: Kong G

Authors: Chiang C, Gamage I, Del Olmo-Garcia M, Pasanen L, Wong H,

Keywords: carcinoid syndrome, carcinoid crisis, urine 5-HIAA, biomarker,

#4303 Carcinoid crisis: Insights from an ENETS Center of Excellence

Introduction: Neuroendocrine neoplasms (NENs) are rare tumours, with up to 30% being functional and associated with carcinoid syndrome (CS). CS commonly presents with flushing, diarrhoea, and hemodynamic instability, and can progress to carcinoid crisis (CC), a severe, potentially fatal complication during surgery or other invasive procedures. The use of prophylactic octreotide infusion peri-operatively remains controversial. The lack of a universal CC definition also poses a challenge for standardised outcome assessments.

Conference:

Presenting Author: Del Olmo-Garcia M

Authors: Del Olmo-Garcia M, Kong G, Wong H, Michael M, Ismail H,

Keywords: carcinoid syndrome, carcinoid crisis, somatostatin analogue, peri-operative management,

#4147 5-Hydroxymethylcytosine profiling of plasma-derived circulating free DNA in patients with pancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE

Introduction: Cell-free DNA (cfDNA) 5-hydroxymethylcystosine (5hmC) analysis, a novel epigenomic technology, can detect changes in tumor gene expression and regulation in liquid biopsies.

Conference:

Presenting Author:

Authors: Sponheim J, Wong C, Thiis-Evensen E, Coruh C, Ning Y,

Keywords: [177Lu]Lu-DOTA-TATE, Lutathera, Peptide Receptor Radionuclide Therapy, Radioligand Therapy, Pancreatic Neuroendocrine Tumor, Biobank, 5-Hydroxymethylation,

#3580 Sex differences in survival of neuroendocrine neoplasia in England 1995–2018

Introduction: Sex differences have been noted at different sites of Neuroendocrine Neoplasia in some registry studies internationally. Analysis of England's National Cancer Registry and Analysis Service (NCRAS) data can help to clarify the significance and importance of this.

Conference:

Presenting Author:

Authors: White B, Chandrakumaran K, Wong K, Rous B, Bouvier C,

Keywords: epidemiology, survival, sex, incidence,

#3575 Claudin 18 immunohistochemistry for determining site of origin of metastatic neuroendocrine tumor

Introduction: Claudin 18 isoform 2 (CLDN18.2) is selectively expressed in normal and neoplastic gastric tissue and some pancreatic neoplasia. Anti-CLDN18.2 is an investigational therapy in gastric and pancreatic adenocarcinoma and a sensitive and specific immunohistochemical marker in these cancers.

Conference:

Presenting Author: Smith B

Authors: Smith B, Rice K, Setthavongsack N, Woltjer R, Wong M,

Keywords: neuroendocrine, immunohistochemistry, claudin 18, CLDN18, gastric,